TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02639533

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
Study: NCT02376283

Intervention type: DRUG
Group type: OTHER
Intervention: ticagrelor
Study: NCT02284672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT03920072

Intervention type: DRUG
Group type: OTHER
Intervention: Burosumab
Description: Burosumab is a sterile, clear, colourless and preservative free solution supplied in single-use 5ml vials containing 1mL of burosumab at a concentration of 30mg/mL
Study: NCT03582228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Envrionment for Social Communication
Description: Once the Virtual Envrionment for Social Communication intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~* 15 minutes- Social support group (guided discussion of experiences related to weekly topic)~* 20 minutes- Didactic instruction~* 15 minutes- Role playing~* 10 minutes- Debriefing and group feedback
Study: NCT03501771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Disposable acupuncture needles will be inserted into acupoints (BL23, BL25, BL40) bilaterally for a depth of 10-30 mm
Study: NCT04872530

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea-protein concentrate
Description: Pea-protein concentrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fava-bean protein concentrate
Description: Fava-bean protein concentrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chickpea protein concentrate
Description: Chickpea protein concentrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red lentil protein concentrate
Description: Red lentil protein concentrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-essential amino acid blend
Description: Non-essential amino acid blend

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate
Description: Whey protein concentrate
Study: NCT03787563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herbal Tea
Description: All participants will be given the intervention in an infusion tea bag. Participant will be instructed to take one tea bag three times a day at before breakfast, lunch and dinner meals. At the time of randomization both active and placebo infusion bag will be provided.There will be one day of washout period after 2 days on treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tea
Description: Similar looking inert placebo tea.
Study: NCT00079131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01392521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib + Refametinib (BAY86-9766)
Description: Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib + Refametinib (BAY86-9766)
Description: Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
Study: NCT00084461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02891616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography-computed tomography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorothymidine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography-magnetic resonance imaging
Study: NCT02982512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Administration of dexmedetomidine a different concetrations
Study: NCT00728767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: The intervention consists of a brief conversation based on the principles of motivational interviewing, including Rollnicks scales to assess the motivation and importance for change. The intervention has duration of about 10 minutes and qualifies as a hybrid between a minimal intervention and a brief intervention.~The intervention also consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol above recommended limits, and a sheet about local alcohol treatment possibilities.~The Intervention group is also offered a brief telephone follow up call 4 weeks later. The purpose of this is to maintain the participant's motivation to reduce drinking.~Employees had been instructed to ask these questions during the intervention: What are you already doing to restrain your drinking? And What can you do more?

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The intervention consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol use above the recommended limits, and a sheet about local alcohol treatment possibilities.
Study: NCT00245219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
Study: NCT04599179

Intervention type: DEVICE
Intervention: self-expandable metal stent
Description: self-expandable metal stent endoscopic positioning
Study: NCT02022176

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose Uptake
Description: Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp
Study: NCT01636661

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: transcranial direct current stimulation- non-invasive brain stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation- non-invasive brain stimulation
Study: NCT00873639

Intervention type: DRUG
Intervention: insulin aspart
Description: Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice

Intervention type: DRUG
Intervention: insulin detemir
Description: Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
Study: NCT03379883

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pulsed radiofrequency (P-RF)
Description: Intra articular RF~Insertion of the RF cannula within the joint. The recommended parameters are a pulse width of 20 msec and a rate of 2 Hz at 42°C for 10min.~Genicular nerve RF ablation.~The RF probe will be placed. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of \< 0.6 V

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP)
Description: Under ultrasound guidance while the patients in a sitting position. In total, 3 to 8 mL of PRP will be injected via the inta-articular route
Study: NCT02022176

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Uptake
Description: Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resting metabolic rate
Description: Resting metabolic rate is measured by indirect calorimetry after an over-night fast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting metabolic rate
Description: Resting metabolic rate is measured by indirect calorimetry after an over-night fast

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nitrite infusion
Description: Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitrite infusion
Description: Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion
Study: NCT03248700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin A tracer
Description: A stable isotope tracer of vitamin A was given orally.
Study: NCT01436162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant + Placebo
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Study: NCT02002585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.
Study: NCT01845298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg
Description: The investigators will administer a single dose of rifampicin 600 mg to study subjects in order to conduct a pharmacokinetic study of rifampicin absorption.
Study: NCT02417298

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.3mg/kg IVP ketamine followed by 0.1mg/kg/hr of ketamine infusion for 3 hours
Study: NCT02080663

Intervention type: PROCEDURE
Intervention: Proximal row carpectomy
Study: NCT03833518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation using motorized glove for stroke and spinal cord injury
Description: Individuals with hand impairment due to stroke or spinal cord injury will wear a motorized glove (Gloreha Sinfonia), or exoskeleton, as part of a rehabilitation protocol to improve dexterity. For each exercise, participants will attempt to do the action, receiving assistance as necessary via powered motors that can move each finger through its passive range of motion based on the current and target position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional MRI for stroke and spinal cord injury
Description: All participants will undergo 3 functional MRI's (fMRI's), two at the beginning of the experiment to document brain activity related to movement intention and ability to sense movement. A third MRI will be performed after the rehabilitation is completed to document the change in brain activity related to movement intention and ability to sense movement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) for stroke and spinal cord injury
Description: Stimulation of the nervous system may be performed using a magnetic stimulator. TMS of the central nervous system is optional. Whether or not a participant undergoes TMS will depend upon their consent, their eligibility for TMS (i.e. no seizure history), and their neurological response to TMS.
Study: NCT01077154

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously for up to 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered subcutaneously for up to 5 years
Study: NCT05740995

Intervention type: DRUG
Intervention: neoadjuvant anti-PD-1 plus chemotherapy
Description: Patients will be given preoperative treatment as below once recruited:~1. Chemotherapy is delivered and composed of two cycles of Nab-paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 3 weeks;~2. PD-1 antibody is delivered 200 mg (iv, in 30 minutes) every 3 weeks;~3. After neoadjuvant therapy of 3-4 cycles, esophagectomy is performed. We advise starting 4 cycles of identical chemoimmunotherapy in 6w after surgery.
Study: NCT03540043

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of Placebo
Description: Botanical Drug Phase 2 clinical study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of PUR0110 (Thykamine) 0.05%
Description: Botanical Drug Phase 2 clinical study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of PUR0110 (Thykamine) 0.1%
Description: Botanical Drug Phase 2 clinical study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of PUR0110 (Thykamine) 0.25%
Description: Botanical Drug Phase 2 clinical study
Study: NCT02555241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mand Training
Description: The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mand Training
Description: The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mand Training
Description: The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Matrix
Description: The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Matrix
Description: The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
Study: NCT03537430

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TNT uniportal VATS mediastinal tumor resection
Description: TNT uniportal video-assisted thoracoscopic surgery refers to the use of conventional uniportal video-assisted thoracoscopic surgery, the use of laryngeal mask anesthesia instead of tracheal intubation anesthesia, intraoperative catheter was not retained, postoperative chest catheter placement.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional uniportal VATS mediastinal tumor resection
Description: The surgical procedures followed principles of mediastinal tumor resection，uniportal video-assisted thoracoscopic surgery in mediastinal tumor resection.
Study: NCT02658474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Group based Acceptance and Commitment Therapy
Study: NCT01802671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation treatment and information
Description: Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment and information
Description: Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment and information
Description: Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)
Study: NCT01720147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin (dietary supplement)
Description: Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required)for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above).
Study: NCT00827047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hemihepatic vascular exclusion
Description: A long vascular clamp is inserted along the midline of the anterior surface of the vena cava,proceed cranially up to the space between the right and the middle hepatic vein trunks. Two tapes are seized with the clamp passing between the anterior surface of the IVC and the liver parenchyma.One tape is use to pass around the hepatic parenchyma for occlusion of the bleeding from the remnant liver;the other is used to loop the right (or left )hepatic vein trunk and short hepatic vein,as well as inferior right hepatic vein,if present. Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection.Thus total hemihepatic vascular exclusion is achieved.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemihepatic vascular Clamping
Description: Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection. Selective clamping can be achieved after carefully dissecting the right from the left hilar branches or after inserting a clamp between the right and left hilar branches without prior hilar dissection and looping the right or left portal structures with a tape.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pringle's Maneuver
Description: Hepatic pedicle clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.